Lantern Pharma (LTRN) Stock Statistics & Valuation Metrics

Lantern Pharma has a market cap or net worth of $48.36M. The enterprise value is $44.77M.

Lantern Pharma has 12,758,872 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lantern Pharma’s return on equity (ROE) is -2.62 and return on invested capital (ROIC) is -21.13%.

The current PE Ratio of Lantern Pharma is ―. Lantern Pharma’s PEG ratio is 0.02.

In the last 12 months, Lantern Pharma had revenue of 0.00 and earned -17.12M in profits. Earnings per share was -1.57.

In the last 12 months, operating cash flow was -15.07M and capital expenditures -567.00, giving a free cash flow of -15.07M billion.

Lantern Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Lantern Pharma upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).

Lantern Pharma as a current ratio of 2.40, with Debt / Equity ratio of 1.71%

In the past 12 months, Lantern Pharma has paid 0.00 in taxes.

Lantern Pharma EV to EBITDA ratio is -6.26, with an EV/FCF ratio of -6.83.

Lantern Pharma has $6.32M in cash and marketable securities with $59.08K in debt, giving a net cash position of $6.26M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Lantern Pharma is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy